Biocon Appoints Shreehas Tambe as CEO & MD From April 1

Biocon Limited has named Shreehas Tambe as its new chief executive officer and managing director, effective April 1, 2026.

The Biocon CEO appointment marks a major leadership shift as the company completes the integration of its biosimilars and generics businesses into a single, unified platform.

Approved by the Nomination & Remuneration Committee and the board, Tambe becomes the first CEO of the integrated Biocon. He will lead a combined business spanning biosimilars and generics, aimed at scaling operations and strengthening global competitiveness. In another key move, Kedar Upadhye has been appointed chief financial officer of Biocon Limited.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

This transition follows the full integration of Biocon Biologics Limited as a wholly owned subsidiary, creating a simplified corporate structure. The company is now positioned to expand in high-growth areas such as diabetes, obesity, oncology, and immunology, supported by a portfolio of biosimilars, insulins, complex generics, peptides, and GLP-1 therapies.

Kiran Mazumdar-Shaw, executive chairperson, Biocon Limited, said: “Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise.

 “It is an honour and privilege to lead Biocon at such a pivotal moment, as we bring together our biologics and generics businesses to build a leading global medicines company.  Biocon is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology. Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs,” said Shreehas Tambe.